Overview

Detailed Summary

Themis Medicare Limited manufactures finished pharmaceutical formulations and synthetic Active Pharmaceutical Ingredients (APIs), operates a hospital-focused commercial division, and exports to over 44 countries while operating three state-of-the-art manufacturing facilities across India with EU GMP certifications for key units.
Q3 FY26 showed a notable profitability turnaround with consolidated revenue of ₹90.13 crore, EBITDA of ₹9.8 crore (10.9% margin) and PAT of ₹10.09 crore, driven by API growth and cost rationalization, despite 9M FY26 revenue falling 20.4% year-on-year to ₹265.7 crore and negative cumulative profitability.
The company is strategically pivoting toward a higher-margin Hospital Business, which contributed 49% of revenue in 9M FY26 versus 38% for FY24-25, reflecting an intentional shift in sales mix and dedicated commercial effort to capture fragmented hospital and critical care segments in India.
Vertically integrated manufacturing capacity, EU GMP approvals, and consistent R&D investment (historical annual spend ~₹13 crore and management guidance of ~3% of revenue) underpin Themis Medicare’s product pipeline and aim to support in-house API consumption and external commercial sales as part of growth plans.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 1,218 Cr
Volatility: High Risk
P/E Ratio: 30.5
Industry P/E: 37.7
PEG Ratio: —
P/B Ratio: 3.3
52W High: 147.99
52W Low: 65.00

Sales CAGR

1Y: 6.22%
3Y: 0.91%
5Y: 15.00%
10Y: 7.79%

Profit CAGR

1Y: -31.46%
3Y: -27.03%
5Y: 8.50%
10Y: 5.27%

ROE

TTM

‌

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
SIGACHI		34.56	1,321 Cr	50.21	2.53	0.29	6.52	6.49	3.13
LINCOLN		635.40	1,283 Cr	13.30	1.69	0.28	11.60	15.18	10.83
THEMISMED		132.20	1,218 Cr	30.47	3.33	0.38	0.42	2.70	6.68
KOPRAN		238.30	1,160 Cr	46.41	2.19	1.25	4.85	6.56	2.75
BAJAJHCARE		338.00	1,135 Cr	49.28	2.13	0.44	8.81	10.79	1.91
BPLPHARMA		1575.00	1,085 Cr	-36.19	3.37	0.06	-2.54	-1.83	-4.89
REMUS		912.75	1,076 Cr	29.08	3.06	0.05	10.54	16.04	7.98
Median: 7 Co.	—	338.00	1,160 Cr	30.47	2.53	0.29	6.52	6.56	3.13

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total

QoQ

YoY

Total

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	98	123	117	94	72	98	78	90	77	87
Expenses	89	94	100	85	77	108	81	80	73	139
Operating Profit	9.30	29	17	8.53	-5.79	-10	-3.10	9.79	3.76	-52
OPM %	9.51	23.73	14.64	9.09	-8.08	-10.33	-3.97	10.86	4.91	-60.28
Other Income	4.67	6.94	5.56	-1.54	-0.36	1.04	4.98	5.93	11	97
Interest	2.16	2.36	2.44	2.79	2.45	2.47	2.76	2.75	2.70	2.98
Depreciation	3.06	2.41	2.45	2.54	2.53	2.55	2.57	2.59	2.60	2.54
Profit Before Tax	8.75	31	18	1.66	-11	-14	-3.45	10	9.06	39
Tax %	24.11	21.24	19.66	68.67	13.12	-1.14	-4.64	2.79	1.88	36.24
Net Profit	6.64	25	14	0.52	-9.66	-14	-3.62	10	8.89	25
EPS in Rs	0.72	2.68	1.55	0.06	-1.05	-1.54	-0.39	1.09	0.96	2.67

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total

YoY

Total

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	236	226	212	184	202	231	395	354	382	406	332
Expenses	194	184	184	181	166	181	299	287	330	356	374
Operating Profit	42	42	27	2.28	36	49	96	67	52	49	-42
OPM %	17.66	18.70	12.85	1.24	17.69	21.46	24.24	19.04	13.49	12.10	-12.66
Other Income	3.19	4.07	5.60	4.94	12	13	18	25	24	11	118
Interest	12	12	12	12	13	13	8.77	9.56	9.38	10	11
Depreciation	12	7.47	7.42	7.99	8.27	8.55	9.48	10	12	9.93	10
Profit Before Tax	17	18	11	-13	27	41	95	73	53	40	55
Tax %	11.16	9.13	0.90	14.59	7.79	13.62	23.49	21.53	18.56	24.81	26.76
Net Profit	15	16	11	-11	25	36	73	57	44	30	40
EPS in Rs	2.19	1.72	1.20	-1.00	2.69	3.88	7.90	6.17	4.72	3.24	4.33
Dividend Payout %	0.00	0.00	0.00	0.00	6.49	11.07	6.32	80.91	10.57	15.43	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total

YoY

Total

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	8.52	9.04	9.18	9.18	9.19	9.19	9.20	9.20	9.20	9.20
Reserves	66	143	160	149	174	209	278	330	368	393
Borrowings	115	66	75	76	89	87	80	92	96	83
Other Liabilities	85	71	61	80	78	65	61	82	93	102
Total Liabilities	275	289	305	314	350	371	428	514	566	588
Fixed Assets	117	124	126	123	116	133	144	162	168	172
CWIP	5.79	8.95	2.47	2.45	7.54	2.47	2.56	2.60	2.60	2.51
Investments	5.64	23	24	27	35	45	56	70	89	95
Other Assets	146	133	153	162	191	191	225	279	307	318
Total Assets	275	289	305	314	350	371	428	514	566	588

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total

YoY

Total

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	26	-1.51	7.86	11	0.33	57	34	16	22	35
Cash from Investing Activity	-7.17	-4.14	-0.04	-3.72	-5.47	-16	-16	-24	-16	-12
Cash from Financing Activity	-13	5.27	-9.11	-9.94	6.72	-26	-18	0.14	-8.77	-26
Net Cash Flow	5.31	-0.38	-1.29	-2.74	1.59	16	1.26	-7.73	-2.62	-3.36

Shareholding History

Quarterly

Yearly

Quarterly

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	67.16%	67.16%	67.15%	67.15%	67.15%	67.15%	67.15%	67.15%	67.15%	67.11%	67.11%	67.11%
FIIs	0.05%	0.01%	0.03%	0.05%	0.10%	0.10%	0.14%	0.00%	0.06%	0.05%	0.11%	0.01%
DIIs	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.11%	0.01%	0.01%	0.01%	0.01%
Public	32.78%	32.82%	32.81%	32.79%	32.74%	32.74%	32.70%	32.74%	32.78%	32.83%	32.78%	32.87%
Total Shareholders	6,970	11,244	11,295	11,322	14,270	17,773	17,889	19,335	22,490	22,576	21,818	21,267

Projection

Investor Presentation

Q1 FY27

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Showing 1 - 8 of 16

‌
‌

AGM/EGM Notice

4 hours ago

Themis Medicare: 56th AGM Notice Published

Themis Medicare published a newspaper advertisement intoning the Notice of the 56th AGM scheduled on 2026-09-30, with details on remote e-voting and book closure.

Frequently Asked Questions about Themis Medicare Ltd

Themis Medicare Ltd (THEMISMED) is currently trading at 132.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Themis Medicare Limited manufactures finished pharmaceutical formulations and synthetic Active Pharmaceutical Ingredients (APIs), operates a hospital-focused commercial division, and exports to over 44 countries while operating three state-of-the-art manufacturing facilities across India with EU GMP certifications for key units. Q3 FY26 showed a notable profitability turnaround with consolidated revenue of ₹90.13 crore, EBITDA of ₹9.8 crore (10.9% margin) and PAT of ₹10.09 crore, driven by API growth and cost rationalization, despite 9M FY26 revenue falling 20.4% year-on-year to ₹265.7 crore and negative cumulative profitability. The company is strategically pivoting toward a higher-margin Hospital Business, which contributed 49% of revenue in 9M FY26 versus 38% for FY24-25, reflecting an intentional shift in sales mix and dedicated commercial effort to capture fragmented hospital and critical care segments in India. Vertically integrated manufacturing capacity, EU GMP approvals, and consistent R&D investment (historical annual spend ~₹13 crore and management guidance of ~3% of revenue) underpin Themis Medicare’s product pipeline and aim to support in-house API consumption and external commercial sales as part of growth plans.

Over the past 52 weeks, Themis Medicare Ltd has traded between a low of ₹65.00 and a high of ₹147.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Themis Medicare Ltd has a market capitalization of approximately 1,218.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Themis Medicare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 30.47 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,218.02 Cr, Themis Medicare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Themis Medicare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Themis Medicare Ltd is 30.47. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Standalone PAT was ₹2.874 crore for the quarter ended June 30, 2026, compared with a loss of ₹1.537 crore in Q1 FY26.

Themis Medicare Ltd

Investor's Suite

Market Explorer

Market Pulse

Deep Dive

Utility

Company

Themis Medicare Ltd

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison

Financial Statements